Eventide Asset Management’s Regulus Therapeutics RGLS Stock Holding History

Eventide Asset Management’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,338	Closed	-$1.4M	–	142
2015 Q4	$1.4M	Hold	1,338	–	–	0.07%	105
2015 Q3	$1.05M	Hold	1,338	–	–	0.06%	106
2015 Q2	$1.76M	Buy	1,338 +371	+38%	+$599K	0.1%	100
2015 Q1	$1.97M	Buy	967 +467	+93%	+$1.01M	0.15%	95
2014 Q4	$962K	Buy	+500	New	+$889K	0.11%	97

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Eventide Asset Management's RGLS Position: Q1 2016 in Review

Eventide Asset Management sold out of Regulus Therapeutics (RGLS) in Q1 2016, closing a stake of 1,338 shares — an estimated $1.4M sold.

Eventide Asset Management first reported a position in RGLS in Q4 2014 and held it in 5 quarters. The position peaked at $1.97M in Q1 2015. 101 funds tracked by Wall St. Rank hold RGLS as of Q1 2016.

Eventide Asset Management reported no remaining Regulus Therapeutics position as of Q1 2016 after selling out during the quarter.
Eventide Asset Management sold 1,338 Regulus Therapeutics shares in Q1 2016, an estimated $1.4M.
Eventide Asset Management first reported a position in Regulus Therapeutics in Q4 2014 and held it in 5 quarters.
Eventide Asset Management's Regulus Therapeutics position peaked at $1.97M in Q1 2015.
101 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2016.

Based on Eventide Asset Management's 13F filing for Q1 2016, filed 16 May 2016.